Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis

• Main Authors: Sumit Bhatnagar (Author), Doerthe Eckert (Author), Sven Stodtmann (Author), In‐Ho Song (Author), Peter Wung (Author), Wei Liu (Author), Mohamed‐Eslam F. Mohamed (Author)
• Format: Book
• Published: Wiley, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Upadacitinib is an orally administered, selective, Janus kinase inhibitor that is approved for several auto‐immune conditions, such as axial spondyloarthritis, an inflammatory rheumatic disease that includes ankylosing spondylitis (AS) and non‐radiographic axial spondyloarthritis (nr‐axSpA)...